NCT03051945

Endogenous Opioid Modulation by Ketamine

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.

Detailed description

This study will test the hypothesis that the rapidly-acting antidepressant ketamine improves core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Ketamine Hydrochloride	Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
OTHER	Normal saline	Placebo

Timeline

• Start date: 2019-08-01
• Primary completion: 2019-08-01
• Completion: 2019-08-01
• First posted: 2017-02-14
• Last updated: 2020-01-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study